We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CDER Prioritized Safety of COVID-19 Products, Opioids in 2022, Report Says
CDER Prioritized Safety of COVID-19 Products, Opioids in 2022, Report Says
In its latest annual report on drug safety priorities, the FDA’s Center for Drug Evaluation and Research (CDER) highlighted the agency’s continued focus on COVID-19 products and its commitment to safety around opioids.